Merz’s Xeomin meets in Phase III trial for PD-associated sialorrhea

The Merz Neurosciences unit of Merz GmbH & Co. KGaA (Frankfurt, Germany) reported top-line data from the Phase III SIAXI trial to treat sialorrhea

Read the full 242 word article

How to gain access

Continue reading with a
two-week free trial.